Business Segments · R&D

Reportable Segment — R&D

Amgen Reportable Segment — R&D increased by 8.9% to $1.90B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 31.0%, from $1.45B to $1.90B.

Analysis

StatementSegment
First reportedQ1 2024
Last reportedQ3 2025
Metric ID: amgn_segment_reportable_segment_research_and_development

Historical Data

6 periods
 Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25
Value$1.34B$1.45B$1.45B$1.49B$1.74B$1.90B
QoQ Change+7.7%+0.2%+2.5%+17.4%+8.9%
YoY Change+10.6%+20.5%+31.0%
Range$1.34B$1.90B
CAGR+32.0%
Avg YoY Growth+20.7%
Median YoY Growth+20.5%
Current Streak5+ quarters growth

Frequently Asked Questions

What is Amgen's reportable segment — r&d?
Amgen (AMGN) reported reportable segment — r&d of $1.90B in Q3 2025.
How has Amgen's reportable segment — r&d changed year-over-year?
Amgen's reportable segment — r&d increased by 31.0% year-over-year, from $1.45B to $1.90B.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.